Disc Medicine Inc. research snapshot
IRON AI stock analysis currently reads Disc Medicine as a clinical-stage hematology biotech with a binary NDA catalyst for bitopertin in erythropoietic protoporphyria (EPP). The analysis is not a certain price prediction. At the July 13, 2026 cutoff, the latest verified close was $76.59, market capitalization was about $2.93 billion, and the main question is whether the FDA will approve bitopertin and how the pipeline beyond it might support long-term value. This is informational research and not investment advice.
Current price
$76.59
Market cap
$2.93 billion
AI score
42 / 100
Rating
High-risk clinical-stage biotech with a binary NDA catalyst
Trend status
Down from 52-week high, elevated short interest
Data cutoff (updated weekly)
July 13, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Disc Medicine is a pre-revenue clinical-stage biotech with a focused hematology pipeline. The business has no revenue, no approved products, and no clear path to profitability before 2028 even in an optimistic scenario. | Medium |
| Moat | The potential moat comes from bitopertin as a first-in-class GlyT1 inhibitor for EPP, orphan drug protections, and specialized heme biology expertise. The moat is unproven until regulatory approval and commercial execution are demonstrated. | Low |
| Management | CEO John Quisel (JD, PhD) leads a team of experienced biotech executives with backgrounds at Roche, AbbVie, and Novartis. Recent insider stock sales by multiple executives raise monitoring flags for alignment assessment. | Medium |
| Financial trend | Zero revenue with quarterly net losses around $60 to $64 million. Cash burn rate is approximately $240 to $260 million per year. The company will likely need additional financing before reaching profitability. | High |
| Valuation | At roughly 11.6x trailing losses with a $2.93B market cap, the stock prices in bitopertin approval and meaningful commercial revenue. Traditional valuation metrics (PE, FCF yield) are not applicable for a pre-revenue biotech. | Low |
| Technical trend | IRON traded in a $40 to $99.50 range over the past 52 weeks and was well off its high. Elevated short interest of 17.33% suggests significant bearish positioning alongside optimistic analyst targets. | Medium |
| Risk level | Very high. Key risks are FDA non-approval of bitopertin, clinical trial failure in pipeline programs, cash burn and dilution, high short interest, securities class action investigation, and key-personnel risk. | High |
| AI confidence | Medium confidence for filing-confirmed financial data and pipeline facts. Low confidence for valuation estimates and probability-weighted outcomes, which depend on binary regulatory events. | Medium data confidence |
| Investment certainty | Low certainty. The binary nature of biotech investing means that the gap between a best case and a worst case is extremely wide, and no analysis can narrow it before the FDA decision. | Low |
IRON AI stock forecast
The IRON AI stock forecast uses scenario ranges around the $76.59 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires FDA approval of bitopertin for EPP, strong launch execution, and pipeline progress. The base case assumes approval but a slow launch or pipeline delays. The bearish case assumes FDA rejection or negative clinical data that leaves the stock trading near cash value.
$140 to $180
More likely if the FDA approves bitopertin without restrictive labeling, the APOLLO Phase 3 confirmatory study reads out positively, DISC-0974 shows strong Phase 2 data in myelofibrosis anemia, and the company maintains a cash runway without excessive dilution.
$60 to $85
More likely if bitopertin is approved but with a narrow label or slow launch, pipeline data is mixed, and the company raises capital at or near current prices, causing mild dilution.
$15 to $35
More likely if the FDA issues a Complete Response Letter for bitopertin, the APOLLO study misses endpoints, or cash constraints force a distressed financing that severely dilutes existing shareholders.
IRON AI technical analysis
IRON AI technical analysis starts from the $76.59 July 10 close used for this July 13 static page. Public technical sources showed the stock off its 52-week high of $99.50 and above its 52-week low of $40.00, with elevated short interest suggesting potential for sharp moves in either direction. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $76.59 | Latest verified close as of the July 13, 2026 data cutoff. |
| Near support | $64 to $68 | The 50-day moving average area where buyers stepped in during the June 2026 pullback. |
| Secondary support | $55 to $58 | The August and October 2025 consolidation zone that served as a prior resistance-turned-support area. |
| Near resistance | $85 to $90 | The recent swing high zone from late June 2026 and the level where multiple analyst targets cluster. |
| 52-week high | $99.50 | November 2025 high. A break above with volume would signal strong bullish momentum. |
| 50-day moving average | About $64 to $68 | The stock was trading above this level at the cutoff, suggesting short-term uptrend momentum. |
| 200-day moving average | About $72 to $76 | The stock was trading near the 200-day moving average, a key long-term trend barometer. |
| Momentum | Mixed, range-bound RSI near 55 | RSI was neutral, neither overbought nor oversold, consistent with a stock in a decision zone ahead of catalysts. |
| Volume | About 324,578 shares | Below the average volume of about 806,505 shares, indicating reduced conviction at current levels. |
| Volatility | High, typical for clinical-stage biotech | Biotech stocks can move 15% to 30% or more on binary events. Position sizing must account for this. |
| Invalidation | Close below $55, then $40 | A close below the $55 area would break the medium-term trading range. A break below $40 (52-week low) would challenge the entire bullish thesis. |
IRON AI trading strategy
The IRON AI trading strategy is a rules-based framework, not personalized advice. For a binary-event biotech like IRON, position sizing and catalyst timing are more important than technical patterns.
Identify the expected FDA decision date for bitopertin and build a position with a defined timeline and maximum loss. Risk only capital you can lose entirely.
Define a maximum loss of 20% to 30% before entering. If the FDA decision is delayed, reassess the position based on new timelines.
If IRON pulls back toward $55 to $60 without negative news and the bitopertin catalyst remains intact, a mean-reversion entry could offer a better risk-reward. Confirm with volume stabilization.
Do not add to a losing position. If the stock breaks below $55 on negative news, the thesis is damaged.
Track FDA review timelines for bitopertin, APOLLO Phase 3 data readouts, DISC-0974 Phase 2 results, quarterly cash burn, financing announcements, and analyst price target changes.
Sell or reduce position if the FDA issues a Complete Response Letter, if the company announces a dilutive financing, or if insider selling accelerates significantly.
Investment research summary
Disc Medicine is a clinical-stage biotech developing novel therapies for hematologic diseases. Its lead asset, bitopertin, targets erythropoietic protoporphyria (EPP), a rare genetic condition causing severe light sensitivity. The company also targets anemia of inflammation and polycythemia vera through its pipeline.
The potential moat is based on first-in-class biology (GlyT1 inhibition for porphyrias), orphan drug exclusivity, specialized heme-regulation expertise, and patents. The actual moat is unproven until regulatory approval and commercial adoption are achieved.
The thesis can fail completely if bitopertin is not approved, if the FDA requires additional trials, if the APOLLO study fails, if pipeline drugs show inadequate efficacy, or if cash burn forces dilutive financing that destroys shareholder value before any product reaches the market.
CEO John Quisel (JD, PhD) leads a team drawn from Roche, AbbVie, and Novartis. The team has relevant regulatory and development experience, but recent insider stock sales totaling over $5 million in the past quarter merit close monitoring.
Disc Medicine operates in hematology, a field with strong unmet need, orphan drug pricing premiums, and growing FDA and investor interest. Rare disease drugs command premium pricing, but the path from approval to profitability is long and capital-intensive.
At $2.93 billion market cap and zero revenue, IRON is priced for bitopertin approval and successful commercialization. The margin of safety is minimal. In a bear case with no approval, the stock could trade near cash value, which is a fraction of the current price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IRON price | $76.59 close on July 10, 2026 | Google Finance and MarketBeat quote snapshots | July 13, 2026 |
| Market capitalization | $2.93 billion, verified as $76.59 x 38,200,000 shares | financial_rigor.py market cap verification and Google Finance | July 13, 2026 |
| Shares outstanding | 38.20 million shares | Google Finance and MarketBeat (consensus 38.18M via cross-validation) | July 13, 2026 |
| EPS (TTM) | -$6.61 | Google Finance | July 13, 2026 |
| 52-week range | $40.00 to $99.50 | Google Finance and MarketBeat | July 13, 2026 |
| Quarterly net income (Q1 2026) | -$63.50 million (EPS -$1.65) | Google Finance quarterly income statement | July 13, 2026 |
| Quarterly cash burn | Approximately $60-64 million per quarter in operating expenses | Google Finance income statement and SEC filings | July 13, 2026 |
| Analyst consensus | Moderate Buy, 11 analysts, average price target $104.44 | MarketBeat analyst ratings | July 13, 2026 |
| Short interest | 17.33% of float, 6.39 days to cover | MarketBeat short interest data | July 13, 2026 |
| Insider and institutional ownership | Insider 3.76%, Institutional 83.70% | MarketBeat ownership data | July 13, 2026 |
| Beta | 0.97 | Google Finance | July 13, 2026 |
This IRON AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 13, 2026 and can be wrong. Clinical-stage biotech investing carries a high risk of total capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
